DexCom, Inc. (NASDAQ: DXCM) develops and markets continuous
glucose monitoring (CGM) products and tools to help adults and pediatric
patients better manage their diabetes. CGM is an FDA-approved technology that
provides real-time readings throughout the day and night, allowing for more
accurate tracking of glucose levels with as many as 288 readings per day.
Utilizing a small sensor just under the skin, the company’s device wirelessly
transmits data to an innovative receiver that vividly displays glucose trends
and alerts patients when they’re outside of the acceptable range. DexCom
currently offers its groundbreaking monitoring systems for ambulatory use by
people with diabetes and for use by healthcare providers in hospitals.
The potential market for this technology is extensive.
According to a report by the Centers for Disease Control and Prevention, more
than 29 million Americans are currently living with diabetes, and it is also
the seventh leading cause of death in the United States. In 2012, diabetes and
its complications accounted for approximately $245 billion in total medical
costs and lost wages.
In the first quarter of 2015, DexCom leveraged this market
potential to realize improved financial results. The company’s total revenue
for the period was $72.8 million, which was a 55 percent year-over-year
increase. Similarly, DexCom realized a 56 percent boost in total gross profit,
recording $46.5 million for the quarter.
The company’s dedication to innovation has placed it in a
strong strategic position to continue expanding its market presence in the
coming months. In April, DexCom introduced a revolutionary app that combined
its CGM technology with the convenience of the Apple Watch™. The DexCom G4®
PLATINUM Continuous Glucose Monitor System with Share™ is an FDA-approved
solution that allows users to discreetly review life-saving glucose data
directly from their wrist or iPhone. Earlier this month, the company expanded
on this innovation by releasing an Android-compatible version of this technology.
“DexCom aims for optimal convenience and accessibility by
providing our patients and their loved ones with access to the most current
technology to better manage their diabetes,” Kevin Sayer, chief executive
officer of DexCom, stated in a news release.
For prospective investors, the company’s established
position within the diabetes management industry should provide a formidable
platform to realize improved returns in the years to come. DexCom’s continued
commitment to innovation and market growth could open the door for sustainable
returns in the future, making the company an intriguing investment opportunity
moving forward.
For more information, visit www.dexcom.com
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
